June 27, 2023 4:50pm

As it closes positive after a session with growing momentum and price appreciators

Pre-open Indications: 3 Hits and 1 Miss

Subscription is coming, it is not conscription but, an offer to join our collective of like-minded investors!  Join me … in the NO spin zone.

Never leave an investor uninformed! Framing the main takeaway … pricing, volume and machine trading creates volatility and liquidity!

If I have learned one thing as a former research analyst in a venture and public fund, operating executive, adjunct (MBA) business school professor now a journalist; it is that your life and your portfolio are largely tied to your knowledge of price movements and questioning pricing targets.

 

The Dow closed UP +212.03 points (+0.63%), the S&P closed UP +49.59 points (+1.15%) while the Nasdaq closed UP +219.90 points (+1.65%)

 

Henry’omics:

We need to more than consider the economic environment - rising rates and inflation to comprehend the micro re “our” universe of cell and gene therapy companies …

Indexes fluctuated through the morning session, then turning positive brining along with the cell and gene therapy sector.

Cause of the jump, consumer confidence soared in June above what economists were anticipating …

On target quote, “This consumer confidence report is simply stunning and indicative that a robust consumer recovery is underway,” wrote Louis Navellier, founder of growth investing firm Navellier & Associates. “In the wake of both surging durable goods orders and consumer confidence, I am now expecting a very healthy June retail sales report.”

Economic Data Docket: Consumer confidence rose to a strong 109.7, higher than the consensus forecast of 105.5 and May's revised 102.5.

  • New orders for durable goods rose 1.7% in May after April's revised 1.2% increase. Shipments of manufactured goods rose 1.7% after falling 0.6% in April.
  • The Case-Shiller home price index rose 0.9%, above views for a 0.5% increase

 

Tuesday (6/27) … RegMed Investors’ (RMi) pre-open: “uncle algorithm, please check out the cell and gene therapy underdogs. This is the week, June and Q2 are coming to an end while Monday’s aftermarket was weak.” … https://www.regmedinvestors.com/articles/13020

 

Pre-open Indications: 3 Hit < Agenus (AGEN +$0.04), Voyager Therapeutics (VYGR -$0.24), Intellia Therapeutics (NTLA -$1.08)> and 1 Miss <Sage Therapeutics (SAGE -$0.88)>

 

RegMed/Stem/Cell and Gene Therapy’s 35 covered equities’ Advance/Decline (A/D) lines: what happened – differences …

  • Tuesday’s advance/decline line opened negative at 6 up/ 26 down and 3 flats, turned positive with 20 up/ 15 down and 0 flat at the mid-day, ending with a positive close of 18 incliners, 15 decliners and 2 flats

 

Key Metrics:

The iShares NASDAQ Biotechnology (IBB) and the SPDR S&P ETF (XBI) indicators:

  • Tuesday, the IBB was down -1.21% and the XBI was down -0.30%

The CBOE Volatility Index (VVIX: INDEX) tracked:

  • Tuesday was down -0.48 point or -3.37% at 13.77

 

Closing Down (10 of 15):

  • Alnylam Pharmaceuticals (ALNY -2.55$ after Monday’s -$1.34),
  • Intellia Therapeutics (NTLA -$1.08 after Monday’s +$0.90),
  • Generation BIO (GBIO -$0.89),
  • Sage Therapeutics (SAGE -$0.88 after Monday’s -$1.83),
  • CRISPR Therapeutics (CRSP -$0.41 after Monday’s +$0.20),
  • Voyager Therapeutics (VYGR -$0.24),
  • uniQure NV (QURE -$0.20 after Monday’s +$0.02),
  • Compass Therapeutics (CMPX -$0.18 after Monday’s +$0.03),
  • Mesoblast (MESO -$0.16),
  • Ultragenyx (RARE -$0.07 after Monday’s -$1.58),

Flats (2):

  • Graphite Bio (GRPH)
  • Sangamo Therapeutics (SGMO)

Closing Up (10 of 18):

  • Regenxbio (RGNX +$1.27 after Monday’s -$0.48),
  • Vericel (VCEL +$0.86 after Monday’s +$0.02),
  • Verve Therapeutics (+$0.69 after Monday’s -$0.45),
  • Blueprint Medicine (BLMC +$0.27 after Monday’s -$1.10)
  • Ionis Pharmaceuticals (IONS +$0.26 after Monday’s -$0.54),
  • BioLife Solutions (BLFS +$0.21 after Monday’s -$0.31),
  • Prime Medicine (PRME +$0.11 after Monday’s -$0.36),
  • bluebird bio (BLUE +$0.10),
  • AxoGen (AXGN +$0.10),
  • Cellectis SA (CLLS +$0.09)

 

Q2/23 – June

  • Tuesday closed positive with 18 incliners, 15 decliners and 2 flats
  • Monday closed negative with 8 incliners, 26 decliners and 1 flat

 

The BOTTOM LINE: I try to keep it simple … and short!

I follow the dictum, quoting Churchill that “short words are best, and the old words when short are best of all.”

A losing session follows a losing week.

After stabs to the heart of share pricing – the execution of electronic and algorithmic trading alleviated losses to turn into … gains as I had predicted yesterday – again I was early!

The only issue is the end of Q2 next week; yet, Q reporting is weeks if not a month away.

Right up front, “I also hate to be so negative or contrarian but, this is a NO spin zone and truth is its product; I can always be WRONG but, I am mostly EARLY!”

Reiterating, there was VALUE out there as electronic trading and algorithms stated their claim to the upside on Tuesday, it’s STILL about playing or betting and timing of the sector.

Unresolved issues --- political investigation of the White House and the Bidens, escalation of the Ukraine war, a Russia uncertainty after a on mercenary versus Russia fight and the major issue - recession - US and global could freezing investors' mood.

A long holiday is upon us, it will be good to get this market and sector out-of-mind and my birthday (7/2)!

 

The top three (3) performing in the session:

·         Tuesday: Regenxbio (RGNX), Vericel (VCEL) – again, and Verve Therapeutics (VERV)

·         Monday: Intellia Therapeutics (NTLA), CRISPR Therapeutics (CRSP) and Beam Therapeutics (BEAM)

While The worst three (3) in the session:

·         Tuesday: Alnylam Pharmaceuticals (ALNY), Intellia Therapeutics (NTLA) and Generation Bio (GBIO)

·         Monday: Sage Therapeutics (SAGE), Ultragenyx (RARE) and Alnylam Pharmaceuticals (ALNY) - again

 

WHY (?) do I keep posting, so investors can get a daily update of the sector's share pricing and some individual companies TRUTHS while electronic trading chews on our portfolio edges.

I am definitely considered a contrarian depending on the session – one has to be a watcher of the ups and downs as well as measurer of sentiment. I am also a NO trust investor but, a validate and verify journalist/analyst.

 

The NO spin zone! U.S. public shareholders deserve accountability …

 

Biostage (OTCQB: BSTG) … so many issues from the past as many of those “miscreant management” members are still employed!

Tuesday closed down-$0.05 with 624 shares traded after Monday closed flat with 0 shares traded, Friday closed down -$0.19 with 2,673 shares traded, Thursday closed down -$0.40 with 5,400, Wednesday closed down -$0.12 with 2,676 shares traded and last Tuesday closed down -$0.08 with 1,523 shares traded <3-month average = 916 shares>

·         Question: Review the number of shares traded on a weekly and monthly basis … is OTCQB: BSTG a Ponzi scheme (with their pump/promote buy and sell agenda) as shares are bought to replace those sold?

·         Accumulated deficit:  $85,901 M – still NO product in sight – a 4-to-5-year clinical trial BEFORE they can evolve to a pediatric protocol!

·         OTCQB: BSTG is holding their annual meeting on 7/19, to vote the Beijing, China designated directors …??? Certainly NOT a US company ANYMORE!

 

My question that resounds, that should be asked is how many companies are at the end of sentiments …  leash?

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.

Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and its or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.